Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2

    September 2022 in “ Journal of The American Academy of Dermatology ”
    Brett King, Manabu Ohyama, Arash Mostaghimi
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document presents the results of two phase 3 trials, BRAVE-AA1 and BRAVE-AA2, involving 654 and 546 patients respectively, testing the efficacy of baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, for severe alopecia areata (AA). The trials used both clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) scales to measure improvement in eyebrow (EB) and eyelash (EL) hair loss. Results showed that by Week 36, a significant proportion of patients on baricitinib (4 mg and 2 mg) showed improvements in EB and EL hair regrowth compared to those on placebo. For instance, in BRAVE-AA1, 31.4% and 32.1% of patients on 4 mg baricitinib achieved 0-1 scores for ClinRO and PRO respectively for eyebrows, compared to 3.2% and 3.1% on placebo. Similar results were observed in BRAVE-AA2. The study concludes that baricitinib demonstrated efficacy in EB and EL hair regrowth, with response rates being similar between ClinRO and PRO measures and consistent across trials.
    Discuss this study in the Community →